Q4 25 EPS
$0.16
MISS 31.06%
Est. $0.23
Q4 25 Revenue
$1.40B
BEAT +2.39%
Est. $1.36B
vs S&P Since Q4 25
-5.9%
TRAILING MARKET
SEM +3.6% vs S&P +9.5%
Full Year 2025 Results
FY 25 EPS
$1.16
MISS 5.55%
Est. $1.23
FY 25 Revenue
$5.45B
BEAT +0.60%
Est. $5.42B
Market Reaction
Did SEM Beat Earnings? Q4 2025 Results
Select Medical delivered a mixed fourth quarter for fiscal 2025, posting earnings that fell well short of expectations even as revenue held up better than feared. The company earned $0.16 per share, missing the $0.23 consensus estimate by 31.06%, whi… Read more Select Medical delivered a mixed fourth quarter for fiscal 2025, posting earnings that fell well short of expectations even as revenue held up better than feared. The company earned $0.16 per share, missing the $0.23 consensus estimate by 31.06%, while revenue of $1.40 billion edged ahead of the $1.36 billion forecast by 2.39%. The profitability shortfall traced most directly to deepening margin pressure in the outpatient rehabilitation segment, where Adjusted EBITDA collapsed 57.9% year-over-year to just $11.18 million, compressing the segment's margin from 8.3% to 3.4%. On a consolidated basis, Adjusted EBITDA declined to $104.66 million from $115.99 million in the prior year, underscoring that the headline earnings improvement was flattered by one-time charges taken in Q4 2024. The strategic backdrop has grown equally complex, with the company having entered a definitive merger agreement to be acquired by a consortium led by Executive Chairman Robert Ortenzio at $16.50 per share. Management guided 2026 revenue of $5.60 billion to $5.80 billion and EPS of $1.22 to $1.32, signaling an expected recovery in earnings power despite ongoing cost headwinds.
Key Takeaways
- • Rehabilitation hospital segment revenue growth of 15.2% driven by expansion from 35 to 38 hospitals and 9.6% increase in admissions
- • Critical illness recovery hospital revenue per patient day increased 5.9% to $2,312
- • Rehabilitation hospital revenue per patient day increased 6.2% to $2,311
- • Outpatient rehabilitation visits increased 4.9% to 2,948,604
- • Interest expense declined 8.3% for full year to $117.9 million
SEM YoY Financials
Q4 2025 vs Q4 2024, source: SEC Filings
SEM Revenue by Segment
With YoY comparisons, source: SEC Filings
SEM Earnings Trends
SEM vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
SEM EPS Trend
Earnings per share: estimate vs actual
SEM Revenue Trend
Quarterly revenue: estimate vs actual
SEM Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 MISS | $0.46 | $0.36 | -21.00% | $1.42B | +0.49% |
| Q4 25 MISS FY | $0.23 | $0.16 | -31.06% | $1.40B | +2.39% |
| FY Full Year | $1.23 | $1.16 | -5.55% | $5.45B | +0.60% |
| Q3 25 BEAT | $0.15 | $0.23 | +48.67% | $1.36B | +2.53% |
| Q2 25 BEAT | $0.24 | $0.32 | +35.19% | $1.34B | -0.66% |
| Q1 25 MISS | $0.45 | $0.44 | -1.54% | $1.35B | -3.02% |